# Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke

Study · id `cardio:ct-nct05885919` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05885919](<https://clinicaltrials.gov/study/NCT05885919>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05885919

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 212 participants.

## Technical summary

Registry record NCT05885919. Randomized; triple masking; primary purpose treatment. Start 2023-07-01 (anticipated); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 212 participants (planned count; ClinicalTrials.gov record NCT05885919, source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)
- Planned start: 2023-07-01 (anticipated) (ClinicalTrials.gov record NCT05885919, source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05885919, source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT05885919, source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05885919, source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05885919-2023-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
- Acronym: EARLYS
- Condition: Ischemic Stroke, Acute
- Condition: Treatment Outcome
- Intervention (Drug): Edaravone Dexborneol Concentrated Solution for injection
- Intervention (Drug): Edaravone Dexborneol placebo
- Lead sponsor: Xiangya Hospital of Central South University
- Lead sponsor class: OTHER
- Collaborator: Jiangsu Simcere Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Xiangya Hospital of Central South University (`cardio:org-xiangya-hospital-of-central-south-university`)
- Registry lists this organization as a collaborator: Jiangsu Simcere Pharmaceutical Co., Ltd. (`cardio:org-jiangsu-simcere-pharmaceutical-co-ltd`)

## Provenance

Content hash: a5fe68a3b4780e801c6f5b5c6e9b48575e39e95256100b24b93aa729ab5e2189
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
